Skip to main content

Efficacy and Safety of Radiofrequency Ablation for Solitary Autonomously Functioning Thyroid Nodules: A Systematic Review and Meta-Analysis

In brief

Radiofrequency ablation normalizes TSH in 76% with solitary thyroid nodules

In 14 studies involving 514 patients, radiofrequency ablation normalized thyroid-stimulating hormone in about three-quarters of patients; nodules shrank by about 81% on average. Complications occurred in 3%, with no permanent complications reported, but efficacy estimates varied widely and the evidence was low certainty. Larger nodules appeared less likely to respond, an issue that needs further study.

Journal
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (Q1)
Published
10 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Naseem Eisa, Mira Khoury
PMID
43008942
DOI
10.1016/j.eprac.2026.11.002

Why clinicians should know about it

  • Picked for Breast and Endocrine Surgery (paper of the day, 11 November 2026): Thyroid nodule ablation offers an organ-sparing alternative to surgery

Abstract

OBJECTIVE: To evaluate the efficacy and safety of radiofrequency ablation (RFA) exclusively for solitary autonomously functioning thyroid nodules (AFTNs). Previous meta-analyses pooled solitary AFTNs with toxic multinodular goiters, potentially confounding RFA efficacy estimates for this specific population. METHODS: A systematic search of PubMed, Embase, CENTRAL, Web of Science, and Scopus (inception to May 2026) identified prospective and retrospective studies of ultrasound-guided RFA for solitary AFTNs with minimum 6-month follow-up. The primary outcome was TSH normalization rate; secondary outcomes included volume reduction ratio (VRR), overall complication rate, and post-ablation hypothyroidism. Proportions were pooled using a random-effects model with the Freeman-Tukey double arcsine transformation. Heterogeneity was assessed using I2 and prediction intervals. Certainty of evidence was rated using the GRADE framework adapted for single-arm proportional meta-analyses. RESULTS: Fourteen studies (514 patients; median follow-up 18 months) were included. The pooled TSH normalization rate was 76.2% (95% CI: 65.7-85.3%; I2 = 84.7%; prediction interval: 37.1-98.9%). The pooled VRR was 80.6% (95% CI: 79.8-81.4%). The overall complication rate was 3.1% (95% CI: 1.5-5.1%; I2 = 0%), with no permanent complications reported. Post-ablation hypothyroidism occurred in 0.4% (2/514). Subgroup analysis suggested higher normalization in nodules <15 mL (80.2%) versus ≥15 mL (58.3%; p = 0.068). GRADE certainty was low for efficacy and moderate for safety. CONCLUSION: RFA achieves TSH normalization in approximately three-quarters of patients with solitary AFTNs, with an excellent safety profile. Baseline nodule volume may influence treatment success. These findings support RFA as a viable organ-sparing alternative for selected patients.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.